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Background. An inﬂuenza A(H1N1)pdm09 infection was diagnosed in a hematopoietic stem cell transplant re-
cipient during conditioning regimen. He was treated with oral oseltamivir, later combined with intravenous zana-
mivir. The H275Y neuraminidase (NA) mutation was ﬁrst detected, and an E119D NA mutation was identiﬁed
during zanamivir therapy.
Methods. Recombinant wild-type (WT) E119D and E119D/H275Y A(H1N1)pdm09 NA variants were generated
by reverse genetics. Susceptibility to NA inhibitors (NAIs) was evaluated with a ﬂuorometric assay using the 2′-(4-
methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) substrate. Susceptibility to favipiravir (T-705) was as-
sessed using plaque reduction assays. The NA afﬁnity and velocity values were determined with NA enzymatic studies.
Results. We identiﬁed an inﬂuenza A(H1N1)pdm09 E119D mutant that exhibited a marked increase in the 50%
inhibitory concentrations against all tested NAIs (827-, 25-, 286-, and 702-fold for zanamivir, oseltamivir, peramivir,
and laninamivir, respectively). The double E119D/H275Y mutation further increased oseltamivir and peramivir 50%
inhibitory concentrations by 790- and >5000-fold, respectively, compared with the WT. The mutant viruses remained
susceptible to favipiravir. The NA afﬁnity and velocity values of the E119D variant decreased by 8.1-fold and 4.5-fold,
respectively, compared with the WT.
Conclusions. The actual emergence of a single NA mutation conferring pan-NAI resistance in the clinical setting
reinforces the pressing need to develop new anti-inﬂuenza strategies.
Keywords. H1N1 inﬂuenza; zanamivir; oseltamivir; resistance; immunosuppression.
Since the 2009 pandemic, inﬂuenza A(H1N1)pdm09
has remained the predominant circulating inﬂuenza
virus in the United States [1, 2] and Europe [1]. Inﬂuen-
za A(H1N1)pdm09 strains are uniformly resistant to
adamantanes owing to the S31N matrix M2 mutation
[1, 2]. However, these strains remain sensitive to neur-
aminidase (NA) inhibitors (NAIs), such as oseltamivir
and zanamivir, the antiviral drugs most frequently used
against inﬂuenza A and B viruses, as well as other NAIs
(eg, peramivir and laninamivir), which are licensed in a
limited number of countries. Laninamivir and zanamivir
share a common binding process to the viral NA enzyme
that involves the 4-guanidino group, which interacts with
the carboxylate of the E119 side chain. By contrast, osel-
tamivir and peramivir contain an acetamide group at the
same position. Consequently, clinical inﬂuenza isolates
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with NA substitutions conferring cross- resistance to zanamivir
and oseltamivir have been infrequently reported [3].
In addition to the effect of the NAI structure, the NA subtype
of the inﬂuenza virus may also inﬂuence the nature of the NA
substitution that could emerge under drug pressure. For instance,
with regard to oseltamivir, the most frequently used NAI, the
H275Y substitution predominates in the neuraminidase 1 (N1)
subtype, such as in the 2009 pandemic and prepandemic A
(H1N1) variants, as well as in avian A(H5N1) strains. By con-
trast, the E119V and R292K substitutions are molecular markers
of oseltamivir resistance in A(H3N2) viruses [4, 5]. Because NA
resistance substitutions involve residues in or in close proximity
to the NA active site, many are likely to inﬂuence viral ﬁtness.
This may explain why such mutant viruses have not become gen-
erally predominant in the community, or the attenuating effect of
these mutations may be neutralized by compensatory or permis-
sive changes similar to those observed in the A/Brisbane/59/2007
background. However, immunosuppression is often associated
with protracted viral replication and can promote the selection
of resistant variants during prolonged exposure to NAIs [6, 7].
We describe the case of an allogeneic hematopoietic stem cell
transplant recipient harboring a multidrug-resistant inﬂuenza
A(H1N1)pdm09 infection associated with pneumonia and sus-
tained viremia mediated by the H275Y/E119D dual NA substi-
tution. Although the H275Y NA mutation is a well-known
marker of N1 resistance to oseltamivir, to our knowledge this
is the ﬁrst report of the actual emergence of zanamivir resistance
due to the E119D N1 NA change.
METHODS
Virus Isolation
From nasopharyngeal (NP) swab specimens collected on day 21
after the onset of inﬂuenzalike symptoms, 400 µL was inoculat-
ed onto duplicate Madin–Darby canine kidney (MDCK) cells
transfected with the cDNA of human 2,6-sialyltransferase
(SIAT1) (European Collection of Cell Cultures) in 24-well plates.
After 1 hour of adsorption at 37°C in a 5% carbon dioxide–
containing atmosphere, 1 mL of infection medium (Dulbecco
plus 2% fetal calf serum, 2 mmol/L glutamine, 0.5 mg/L trypsin,
20 mmol/L HEPES, 1% dimethyl sulfoxide, and antibiotics) was
added before reincubation. Cells were monitored daily with
light microscopy for the presence of cytopathic effects. Superna-
tants were recovered 2 and 7 days after inoculation.
Quantitative Real-Time Reverse-Transcription Polymerase
Chain Reaction Analysis
The viral genome was extracted from 400 µL of respiratory or
plasma specimen individually using the NucliSENS easyMAG
nucleic acid kit (bioMérieux). A quantitative real-time re-
verse-transcription polymerase chain reaction (RT-PCR) assay
[8] was performed using One-Step SuperMix (Invitrogen) in a
StepOne Real-Time PCR System (Applied Biosystems). Values
below the usual routine positive threshold (<500 copies/mL)
were arbitrarily given a value of 250 copies/mL.
Sanger Sequencing Analysis
Extracted viral genome was used for the synthesis of comple-
mentary DNA using SuperScript II reverse-transcriptase
(Invitrogen) and Uni12W primer updated from previously pub-
lished assays [9]. The NA gene was ampliﬁed by PCR using Am-
pliTaq polymerase (Applied Biosystems). First-round PCR was
done with primers cswN1F1 (5′-AGCAAAAGCAGGAGTT
TAAAATG-3′) and cswN1R1440 (5′-TAGTAGAAACAAGG
AGTTTTTTTGA-3′), followed by 2 independent heminested
PCR assays: one with primers cswN1F1 and cswN1R1099 (5′-
CCTATCCAAACACCATTGCCGTAT-3′) and the other with
primers cswN1F401 (5′-GGAATGCAGAACCTTCTTCTTG
AC-3′) and cswN1R1440 (sequences provided by Rod Daniels,
Medical Research Council, London, United Kingdom). Ampli-
cons were sequenced with primers cswN1F1, cswN1R1099,
cswN1F401, cswN1R1440, and cswN1R424 (5′-GTCAAGAA
GAAGGTTCTGCATTCC-3′), using conventional Sanger se-
quencing performed with the ABI 3500 × L Genetic Analyzer
(Applied Biosystems).
High-Throughput Sequencing Analysis
High-throughput sequencing was performed on 4 selected sam-
ples for an in-depth analysis of the viral genome and to inves-
tigate the evolution of viral quasispecies populations. The viral
nucleic acid extraction and the high-throughput RNA sequenc-
ing library preparation procedures were performed as described
elsewhere [10]. Specimens were sequenced using the 100-bp
paired-end protocol, with indexing on a HiSeq 2500 (Illumina)
sequencer. To estimate quasispecies sequence diversity, read-
ings were ﬁrst mapped [11] to all segments of the reference ge-
nomes (A/Brisbane/15/2011 and A/Frankfurt/INS403/2010),
and the results were then analyzed [12] to infer the structure
of the viral population and the nucleotide sequence composi-
tion within each specimen (see Supplementary Tables 1–3).
Generation and Characterization of Recombinant Inﬂuenza
A(H1N1)pdm09 Viruses
Reverse genetics and site-directed mutagenesis were used to
generate the recombinant wild-type (WT), E119D, and
E119D/H275Y inﬂuenza viruses in the background of A/Que-
bec/144147/09 (an A(H1N1)pdm09-like virus; GenBank acces-
sion Nos. FN434457-FN434464), as described elsewhere [13].
These recombinants were tested by NA inhibition assays
using the 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic
acid (MUNANA; Sigma) ﬂuorescent substrate for their suscept-
ibility to laninamivir, zanamivir, oseltamivir and peramivir. Re-
combinant viruses were standardized to an equivalent dose of
106 plaque-forming units/mL and used in a MUNANA-based
assay to determine maximal velocity (Vmax) and Michaelis
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constant (Km) enzymatic parameters [14]. The phenotype of
resistance to favipiravir (T-705) was determined by plaque re-
duction assays [15] using ST6GalI (MDCK-α2,6) cells. Recom-
binant WT, E119D, and E119D/H275Y A/Quebec/144147/09
NA proteins were expressed in human embryonic kidney
(293T) cells to assess their surface NA activity [16].
NA Protein Structure Analysis
Consensus DNA sequences from clinical specimens and the se-
quences used for in vitro studies (A/Quebec/144147/09) were
translated, modeled, and evaluated using the Modeller software
package version 9.13 [17] to conﬁrm that substitutions do not
elicit structural changes outside the drug-binding pocket, which
could affect functionality and/or stability. Models were built
and optimized using reference structures “N1 NA H275Y +
oseltamivir” (Protein Data Bank [PDB] code, 3CL0) and “N1
NA H275Y + zanamivir” (PDB code, 3CKZ). These structures
were chosen because they contain the 3-dimensional conﬁgura-
tions of the particular residues required for coordinating inhibi-
tor binding. In brief, translated consensus NA sequences served
as input for structure-guided sequence alignment to reference
sequences using the ‘align2d’ command in Modeller. For each
NA consensus sequence (including A/Quebec/144147/09), 100
models were built using the automodel class. The best models
were selected (based on evaluation with the discrete optimized
protein energy “DOPE” score) for subsequent structural analysis.
Using the PyMOLmolecular graphics system [18], the backbones
of the models were structurally aligned to the reference structures
to highlight any potential large (>2 angstroms) structural differ-
ences. To analyze residues in the binding pocket, side-chain
differences (rotamer conﬁgurations and displacement between
models and references) were calculated using the measurement
tools within the PyMOL system; all related images were generated
in this system.
Ethical Considerations
After submission of the case to the University of Geneva Hos-
pitals’ ethics committee, the requirement for informed consent
was waived.
RESULTS
Patient Description
A 63-year-old white male patient with relapsing acute myeloid
leukemia was admitted to the hospital in February 2014 for mis-
matched-donor allogeneic hematopoietic stem cell transplanta-
tion (HSCT). At day 1 after admission, during HSCT reduced
intensity conditioning with antilymphocytic serum, ﬂudara-
bine, and melphalan and while he was profoundly neutropenic
(leukocytes, <0.5 giga/L), the patient developed fever, sore
throat, and a cough. Empiric treatment was immediately started
with intravenous piperacillin-tazobactam (4.5 g/8 h) and
vancomycin (1 g; single dose) and oral oseltamivir. Oseltamivir
was stopped after 24 hours because of a negative real-time RT-
PCR screening assay result for inﬂuenza A/B viruses in naso-
pharyngeal secretions. At day 9 after admission and symptom
onset, the patient received the peripheral hematopoietic stem
cell infusion (unrelated donor; HLA compatibility, 9/10) with-
out any complications; graft-vs-host disease (GVHD) prophy-
laxis consisted of cyclosporine and mycophenolate mofetil.
Persistence of fever and worsening of respiratory symptoms at
day 1 after HSCT (day 10 after symptom onset) prompted tho-
racic computed tomographic imaging, which showed new
ground-glass pulmonary inﬁltrates and condensations in all pul-
monary lobes, associated with small bilateral pleural effusions.
The same day, a new nasopharyngeal swab specimen was positive
for inﬂuenza A RNA (4.8 ×106 copies/mL), suggesting pneumo-
nia due to the inﬂuenza virus infection. Oral oseltamivir therapy
(150 mg twice daily) was then resumed. The nasopharyngeal
specimen collected at admission was reanalyzed with multiple
different PCR assays. One speciﬁc assay targeting H1 revealed a
slightly positive signal (cycle threshold, 37), suggesting an infec-
tion in its very early phase. This signal was below the positive
threshold (<500 copies/mL) of the inﬂuenza A screening assay
used routinely andmay have explained why the initial assay result
was negative. Subsequently, all respiratory samples yielded posi-
tive results for inﬂuenza A for the next 12 days, with a respiratory
viral load peaking at 8.5 ×107 copies/mL (Figure 1).
Despite oseltamivir therapy, the patient’s respiratory viral load
continued to increase (Figure 1). On day 3 after HSCT (day 12
after symptom onset), the patient presented with hemoptysis, sug-
gesting an alveolar hemorrhage as well as multiorgan failure, re-
quiring intensive care unit admission and intubation. The next
day, intravenous zanamivir (600 mg twice daily) was added to
oseltamivir on a compassionate-use basis owing to the severity
of the clinical presentation. The patient’s condition initially im-
proved, with resolution of fever and a decrease in ventilation
parameters, but subsequently worsened again. Intravenous meth-
ylprednisolone (125 mg once daily) was introduced at day 10 after
HSCT (day 19 after symptom onset) for suspected acute digestive
GVHD presenting with diarrhea, which was later conﬁrmed by
duodenal biopsy. Engraftment occurred at day 12 after HSCT
(day 21 after symptom onset), and oseltamivir treatment was
stopped because of lack of improvement. Despite zanamivir treat-
ment, the patient’s general and respiratory evolution was thereaf-
ter unfavorable. At day 18 after HSCT (day 27 after symptom
onset), a left middle cerebral artery ischemic stroke associated
with cerebral herniation led to the patient’s death.
Virologic Investigations
In the ﬁrst quantiﬁable swab specimen (day 9 after symptom
onset), Sanger sequencing allowed the identiﬁcation of the
H275Y mutation in the NA gene. Importantly, the patient
had received 24 hours of oseltamivir treatment 8 days earlier.
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High-throughput sequencing investigations revealed a mixed
population of WT (275H; 45.3%) and mutated (275Y; 54.7%)
viruses (Figure 2A). The mutated virus then became dominant
with oseltamivir and zanamivir treatment as high-throughput
sequencing of the nasopharyngeal samples performed on days
15 and 21 after symptom onset showed proportions of mutated
(275Y) viruses of 94.1% and 100%, respectively (Figure 2A).
Nasopharyngeal specimens collected on days 9 and 15 after
symptom onset showed a 100% population of E119. In the
specimen collected pm day 21 after symptom onset and after
8 days of zanamivir treatment, an E119D substitution appeared
in a mixed population (119E, 22.4%; 119D, 72%), the remaining
readings being intermediary 119G (5.1%) and 119A (0.5%)
(Figure 2B). The respiratory specimen displaying the H275Y
Figure 1. Evolution of upper respiratory and plasma viral load according to neuraminidase inhibitor treatment. Abbreviations: HSCT, hematopoietic stem
cell transplantation; HTS, high-throughput sequencing; ICU, intensive care unit; SS, Sanger sequencing.
Figure 2. Proportion of quasi-species at codons 275 (A) and 119 (B) of the neuraminidase by high-throughput sequencing.
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change and a mixed 119E and 119D population was cultivated
in the absence of zanamivir in duplicate. The H275Y and
E119D substitutions persisted in the culture stopped after 2
days (moderate cytopathic effect), whereas the culture stopped
7 days after inoculation (stronger cytopathic effect) had the WT
genotype for both 119 and 275 codons.
Reverse genetics were used to assess the impact of the E119D
mutation in vitro. In NA inhibition assays, the single E119D
variant exhibited highly-reduced susceptibility to zanamivir,
peramivir, and lanimivir and reduced susceptibility to oseltami-
vir (50% inhibitory concentration increments of 827-, 286-,
702-, and 25-fold vs WT, respectively) (Table 1). Oseltamivir
and peramivir resistance levels were further enhanced in the
double E119D/H275Y mutant. All viruses remained susceptible
to favipiravir. The E119D substitution caused a signiﬁcant
decrease in the NA afﬁnity (Km, 471.29 vs 58.31 µmol/L) and
velocity (Vmax, 3.22 vs 14.40 U/s) compared with the WT
(Table 2). This change also signiﬁcantly reduced surface NA ac-
tivity (69.4% of the WT) when testing was performed using re-
combinant NA proteins.
The Km and Vmax values for the double E119D/H275Y mu-
tant virus were 252.29 µmol/L and 1 U/s, respectively, whereas
the double E119D/H275Y mutant protein demonstrated only
10% of surface NA activity compared with the WT (Table 2).
The single E119D genotype (codon GAC) was maintained
after 4 passages in MDCKα2,6 cells without zanamivir. By con-
trast, after only 2 passages, this codon was replaced by a mixture
of GAA and GAG codons, with both coding for glutamic acid
(E) in the passage of the double E119D/H275Y mutant (data
not shown). This D119E reversion was accompanied by the re-
turn to the susceptible phenotype against zanamivir and lanina-
mivir and conserved resistance to oseltamivir and peramivir
(data not shown). As expected, the double (E119D/H275Y) mu-
tation was maintained when cell culture passages were per-
formed in the presence of zanamivir (ﬁnal concentration, 0.1
or 1 µmol/L).
Because amino acid substitutions can alter protein backbone
conformation (eg, NA epitopes) and inﬂuence functionality, we
built models to assess the degree of structural similarity of the
recombinant NA proteins used for in vitro studies to WT struc-
tures bound to either oseltamivir or zanamivir (PDB code, 3CL0
and 3CKZ) (Figure 3). Structural alignments conﬁrm that our
recombinant NA proteins, and those found in clinical speci-
mens, are almost identical to known structures and have similar
drug-binding pockets (Figure 3B and 3C).
Plasma specimens collected at days 13 and 16 were positive
for inﬂuenza by quantitative real-time RT-PCR, with a viral
load of 3.2 ×103 and 4.7 ×103 copies/mL, respectively (Figure 1).
Other plasma specimens collected were positive between days
11 and 24 after symptom onset, but quantiﬁcation was not pos-
sible due to inappropriate storage (data not shown). Owing to a
low viral load in blood, it was not possible to culture the virus
and conﬁrm the presence of infectious virus in blood.
DISCUSSION
The resistance pattern for N1 viruses observed so far has fol-
lowed mostly a dichotomous pattern, either spreading in the
community without drug pressure [19–21] or limited to highly
immunosuppressed hosts treated with antivirals [22, 23]. In the
ﬁrst situation, viral ﬁtness is often preserved, possibly because of
other mutations in the NA, whereas ﬁtness is often decreased in
the second instance. NA substitutions do not generally confer
cross-resistance to zanamivir and oseltamivir owing to the dif-
ferences between these agents in chemical structure and binding
afﬁnity to the active site of the NA enzyme. One notable excep-
tion is the R292K substitution, which confers a high level of re-
sistance to oseltamivir and reduced inhibition to zanamivir in
H3N2 viruses [3]. The H275Y mutation described elsewhere
in H5N1- and H1N1-infected patients [24, 25] impairs the
full rotation of E277 (Figure 3B–D), which is necessary for osel-
tamivir but not for zanamivir high-afﬁnity binding [26].
Table 1. Phenotypic Susceptibility to NAIs and Favipiravir in Recombinant Viruses Containing NA Mutations Identified in a Clinical
A(H1N1)pdm09 Isolate
Recombinant
A(H1N1)
pdm09 Virus
IC50, Mean (SD), nmol/L [Fold Increase]
a
IC50 for Favipiravir,
µg/mLbZanamivir Oseltamivir Peramivir Laninamivir
WT 0.94 (0.03) [1] 2.03 (0.01) [1] 0.14 (0.02) [1] 0.29 (0.03) [1] <1
E119D 778 (64.5) [827] 50.82 (7.8) [25] 40.08 (2.6) [286] 203.63 (9) [702] <1
E119D/H275Y 849.13 (31.44) [903] 1605.26 (31.44) [790] 834.19 (54.9) [5958] 106.31 (7.69) [366] <1
Abbreviations: IC50, 50% inhibitory concentration; NA, neuraminidase; NAIs, NA inhibitors; SD, standard deviation; WT, wild type.
a The phenotype of susceptibility to NAIs was determined by NA inhibition assays using the fluorescent 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid
(MUNANA)CSITALICSTART CSITALICENDsubstrate; IC50 values are means from 3 independent experiments. Fold increases are in comparison with the
recombinant WT virus.
b The phenotype of susceptibility to favipiravir (T-705) was determined by plaque reduction assays using an agarose overlay containing favipiravir at final
concentrations ranging from 0.1 to 100 µg/mL. In 2 independent experiments, the 1-µg/mL concentration completely inhibited plaque formation for all tested
recombinants.
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Between 2007 and 2009, most seasonal A/Brisbane/59/2007
(H1N1) strains acquired this mutation, thus highlighting a pre-
served viral ﬁtness despite the absence of antiviral pressure [27].
This phenomenon was attributed to permissive NA mutations,
whose presence in that background may have facilitated the
emergence and worldwide spread of the H275Y variant [16,
28]. Fortunately, global prevalence of the H275Y NA mutation
in the A(H1N1)pdm09 background has remained sporadic
worldwide since 2009 [29–32].This risk may eventually increase
because most A(H1N1)pdm09 circulating strains carry V241I
and N369K NA mutations that have a potential permissive ef-
fect [33, 34].Moreover, these 2 mutations have been recently re-
ported in oseltamivir-resistant community clusters with no
previous NAI exposure [35, 36]. Immunosuppression and pre-
vious oseltamivir treatment are known risk factors for resistance
selection [6, 7, 22]. The rapid emergence of the H275Y mutation
in our patient suggests it was already present within the viral
population and selected during oseltamivir treatment.
Figure 3. Neuraminidase 1 (N1) molecular detail. A, N1 protein highlighting residues (shaded orange) that bind oseltamivir (blue molecule) and zanamivir
(purple molecule) inhibitors. B, C, Details of the binding pocket from N1 used for in vitro studies (green side chains) aligned to structure Protein Data Bank
codes 3CL0 (B) and 3CKZ (C) (gray backbones, orange side chains). D, Overlay of known structure (orange and gray), in vitro model (green side chains), and
model from day 21 specimen (cyan side chains). The positively charged guanidino group of zanamivir (highlighted in blue on the 2D chemical structure inlay)
forms 2 salt bridges with E119 (green dotted lines) that stabilize zanamivir binding. The shorter side chain of 119D (cyan) allows only 1 salt bridge to this
guanidino group (red dotted line). This reduced ability to form salt bridges with zanamivir probably destabilizes inhibitor binding.
Table 2. Enzymatic Properties of the NA Protein of Recombinant Influenza A(H1N1)pdm09 Viruses
Recombinant
A(H1N1)pdm09 Virus Km, Mean (SD) µmol/L
a Vmax, Mean (SD), U/s
a Vmax Ratio
a
Surface NA Activity,
Mean, (SD) %b
WT 58.31 (4.29) 14.40 (0.62) 1 100
E119D 471.29 (46.5)c 3.22 (0.58)d 0.22 69.4 (0.75)c
E119D/H275Y 252.29 (27.14)c 1 (0.22)e 0.07 10 (1.03)d
Abbreviations: Km, Michaelis constant; NA, neuraminidase; SD, standard deviation; Vmax, maximum velocity; WT, wild type.
a Recombinant viruses were used at a standardized amount of 106 plaque-forming units to determine NA enzyme kinetic parameters. Values represent mean Km and
Vmax from a representative experiment performed in triplicate.
b Recombinant NA proteins were expressed in 293T cells for the determination of surface NA activity using the fluorescent 2′-(4-methylumbelliferyl)-α-D-N-
acetylneuraminic acid (MUNANA) substrate. Values represent mean NA activity relative to the recombinant WT protein from triplicate experiments.
c P < .05 (vs recombinant WT).
d P < .01 (vs recombinant WT).
e P < .001 (vs recombinant WT).
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Glutamic acid at position 119 is highly conserved in inﬂuenza
A and B NAs. This residue is known to stabilize the NA catalytic
site and therefore enhances cleavage of sialic acid residues [37].
Besides its interaction with the sialic acid substrate, E119 plays a
crucial role in the binding of the NA enzyme to the guanidine
group present in zanamivir, laninamivir and peramivir (Fig-
ure 3D). E119 is also involved in the interaction between the
NA enzyme and the C4 hydroxyl group present in oseltamivir.
The replacement of glutamic acid (E) by aspartic acid (D),
which has a shorter side chain, may alter these interactions
and result in the cross-resistance phenotype. Indeed, our 3-
dimensional structure analysis revealed that although the overall
integrity of the binding pocket is maintained, the shorter side
chain of 119D removes 1 of 2 salt bridges that coordinate the
guanidine group of zanamivir (Figure 3D).
Other substitutions of residue E119 may result also in altered
binding processes and NAI resistance in inﬂuenza A or B var-
iants. A change to glycine or alanine (as observed on day 21), or
even valine (nonpolar side chain) at position 119 would remove
both interactions, thus further destabilizing inhibitor binding.
E119 V is a known marker of oseltamivir resistance in H3N2
viruses. The same substitution conferred cross-resistance to za-
namivir, peramivir, oseltamivir, and A-315675 when intro-
duced in recombinant inﬂuenza A/WSN/33 (H1N1) variants
[38]. A similar resistant phenotype was obtained in the A
(H1N1)pdm09 E119V recombinant [13]. More recently, we re-
ported the selection of the E119K NA substitution in inﬂuenza
A(H1N1)pdm09 viruses submitted to laninamivir pressure in
vitro [14]. Therefore, it is plausible that the E119D mutation re-
covered in our patient was due to zanamivir pressure. Neverthe-
less, the simultaneous presence of the E119D and H275Y
mutations in the A(H1N1)pdm09 background is worrisome be-
cause of the resulting multidrug-resistant phenotype.
The E119D mutation was initially absent in our patient and
appeared after 8 days of zanamivir treatment in a mixed popu-
lation, with >70% harboring the 119D codon. As shown in Fig-
ure 1, there was a slight transient decrease in viral load after
zanamivir introduction, followed by a secondary increment.
This could be explained by the induction of in vivo resistance
(E119D) but may also be explained by an increase of immuno-
suppression secondary to GVHD. Owing to this secondary 5–
10-fold increase in respiratory viral load, it can be hypothesized
that the ﬁtness of the viral mutant was relatively preserved
under drug pressure. Although it has still to be proved, one
may speculate that the viral mutant detected in our immuno-
suppressed patient would have been cleared in an immunocom-
petent patient.
The double mutant E119D/H275Y virus demonstrated ex-
tensive resistance to all NAIs. A few reports have described in
vivo resistance to oseltamivir, zanamivir, and peramivir [23,
39] in patients carrying a double mutation (ie, H275Y and
I223R). Nevertheless, the level of resistance to zanamivir was
relatively low in these cases. Recently, Baek et al [40] showed
that recombinant inﬂuenza A/California/04/2009 [A(H1N1)
pdm09] viruses harboring E119D and E119D/H275Y muta-
tions also displayed reduced sensitivity to oseltamivir, zanami-
vir and peramivir with a synergistic effect being observed for the
double E119D/H275Y mutant compared with the single E119D
mutant. However, in that report, both the single (E119D) and
double (E119D/H275Y) variants were found to be genetically
stable after 4 passages in MDCK cells, as well as in mice. By con-
trast, in our double (E119D/H275Y) recombinant mutant, the
E119D mutation reverted to the WT genotype after 2 passages,
whereas the E119D genotype was not altered after cell-culture
passaging of the single mutant.
Thus, our ﬁndings suggest a compromising effect for the dou-
ble mutation that could be attributed to the more detrimental im-
pact on the NA velocity (Vmax) and cell surface NA activity
observed in our experiments (Table 2). The fact that the E119D
NA mutation was present in a mixed population in our clinical
specimen impaired the ability to accurately determine the impact
of this change on the A(H1N1)pdm09 NA properties. On the
other hand, this information could be obtained by the use of re-
verse genetics. It should be noted that the NA proteins from the
clinical isolates described in this study share approximately 98%
amino acid identity with our recombinant (A/Quebec/144147/
09) virus and exhibit almost identical structures (Figure 3). In ad-
dition, there was a 98.4% amino acid identity between the HA of
A/QC/144147/09 and that of the clinical isolate, suggesting a
close genetic and antigenic relationship among these strains.
The most striking feature of our study is that the single
E119D mutation alone led to increased resistance to all NAIs.
To our knowledge, this is the ﬁrst clinical report of a single mu-
tation conferring pan-NAI resistance and highlights the plastic-
ity of inﬂuenza viruses and their endless ability to evolve [41].
Due to intrinsic resistance to the adamantanes, there is no effec-
tive antiviral treatment against an inﬂuenza A(H1N1)pdm09
virus harboring the E119D mutation, except favipiravir, an in-
hibitor of the viral RNA polymerase [15], which is currently not
licensed. These results conﬁrm the importance of monitoring
drug resistance and the continuous need for antiviral research
and development.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regard-
ing errors should be addressed to the author.
Notes
Acknowledgments. We acknowledge Caroline Tapparel for her con-
structive criticism, Bruno Lina for his work, and Rosemary Sudan for edito-
rial assistance.
1732 • JID 2015:212 (1 December) • L’Huillier et al
Disclaimer. The funders had no role in study design, data collection
and analysis, the decision to publish, or preparation of the manuscript.
Financial support. This work was supported by the Laboratory of Vi-
rology in Geneva (research grant), the Swiss Federal Ofﬁce of Public Health
(grant 11.004805/301.0001-705), the Swiss National Foundation (grant
32003B-146993), and the Canadian Institutes of Health Research (grant
229733 to G. B.).
Potential conﬂicts of interest. T. J. P. has received a research grant from
the Louis-Jeantet Foundation. Y. C. has served as a consultant for Novartis,
Bristol-Myers Squibb, Pﬁzer, and Ariad, and Merck Sharp & Dohme and
Celgene have contributed to his meeting expenses. G. B. has received re-
search grants from GlaxoSmithKline, Canadian Institutes of Health Re-
search, and Biota. L. K. has received research grants from the Swiss
Federal Ofﬁce of Public Health, the Swiss National Science Foundation,
and the University of Geneva Hospitals. All other authors report no poten-
tial conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. World Health Organization. Review of the 2013–2014 winter
inﬂuenza season, northern hemisphere. Wkly Epidemiol Rec 2014;
89:245–56.
2. Epperson S, Blanton L, Kniss K, et al. Inﬂuenza activity - United States,
2013–14 season and composition of the 2014–15 inﬂuenza vaccines.
MMWR Morb Mortal Wkly Rep 2014; 63:483–90.
3. McKimm-Breschkin JL. Inﬂuenza neuraminidase inhibitors: antiviral
action and mechanisms of resistance. Inﬂuenza Other Respir Viruses
2013; 7(Suppl 1):25–36.
4. Zurcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resis-
tance in human inﬂuenza virus N2 neuraminidases compromise virus
ﬁtness and are not stably maintained in vitro. J Antimicrob Chemother
2006; 58:723–32.
5. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neur-
aminidase mutation H274Y conferring resistance to oseltamivir on
the replicative capacity and virulence of old and recent human inﬂuenza
A(H1N1) viruses. J Infect Dis 2010; 201:740–5.
6. World Health Organization. Oseltamivir resistance in immunocompro-
mised hospital patients. Pandemic (H1N1) brieﬁng note 18. 2009.
http://www.who.int/csr/disease/swineﬂu/notes/brieﬁng_20091202/en/.
Accessed 16 December 2014.
7. Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients
with oseltamivir-resistant pandemic (H1N1) 2009, United States.
Emerg Infect Dis 2011; 17:255–7.
8. Piralla A, Daleno C, Pariani E, et al. Virtual quantiﬁcation of inﬂuenza
A virus load by real-time RT-PCR. J Clin Virol 2013; 56:65–8.
9. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer
set for the full-length ampliﬁcation of all inﬂuenza Aviruses. Arch Virol
2001; 146:2275–89.
10. Petty TJ, Cordey S, Padioleau I, et al. Comprehensive human virus
screening using high-throughput sequencing with a user-friendly repre-
sentation of bioinformatics analysis: a pilot study. J Clin Microbiol
2014; 52:3351–61.
11. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2.
Nat Methods 2012; 9:357–9.
12. Zagordi O, Bhattacharya A, Eriksson N, Beerenwinkel N. ShoRAH: es-
timating the genetic diversity of a mixed sample from next-generation
sequencing data. BMC Bioinformatics 2011; 12:119.
13. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characteriza-
tion of recombinant pandemic inﬂuenza A(H1N1) viruses resistant to
neuraminidase inhibitors. J Infect Dis 2011; 203:25–31.
14. Samson M, Abed Y, Desrochers FM, et al. Characterization of drug-
resistant inﬂuenza virus A(H1N1) and A(H3N2) variants selected
in vitro with laninamivir. Antimicrob Agents Chemother 2014; 58:
5220–8.
15. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV.
In vitro antiviral activity of favipiravir (T-705) against drug-resistant in-
ﬂuenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother
2010; 54:2517–24.
16. Abed Y, Pizzorno A, Bouhy X, Boivin G. Role of permissive neuramin-
idase mutations in inﬂuenza A/Brisbane/59/2007-like (H1N1) viruses.
PLoS Pathog 2011; 7:e1002431.
17. Sali A, Blundell TL. Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 1993; 234:779–815.
18. PyMOL. The PyMOL molecular graphics system. Version 1.7.4. http://
www.pymol.org. Accessed 7 May 2015.
19. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant inﬂuenza A
pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis
2009; 15:1970–2.
20. Le QM, Wertheim HF, Tran ND, et al. A community cluster of oselta-
mivir-resistant cases of 2009 H1N1 inﬂuenza. New Engl J Med 2010;
362:86–7.
21. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-
resistant inﬂuenza viruses A (H1N1), Norway, 2007–08. Emerg Infect
Dis 2009; 15:155–62.
22. Centers for Disease Control and Prevention. Oseltamivir-resistant novel
inﬂuenza A (H1N1) virus infection in two immunosuppressed patients
- Seattle, Washington, 2009. MMWR Morbid Mortal Wkly Rep 2009;
58:893–6.
23. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV.
Recovery of a multidrug-resistant strain of pandemic inﬂuenza A
2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a
child after prolonged treatment with oseltamivir. Clin Infect Dis
2010; 51:983–4.
24. Le QM, Kiso M, Someya K, et al. Avian ﬂu: isolation of drug-resistant
H5N1 virus. Nature 2005; 437:1108.
25. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the inﬂu-
enza A/H1N1 neuraminidase active site following oseltamivir phos-
phate treatment leave virus severely compromised both in vitro and
in vivo. Antiviral Res 2002; 55:307–17.
26. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-re-
sistant inﬂuenza virus neuraminidase mutants. Nature 2008;
453:1258–61.
27. Moscona A. Global transmission of oseltamivir-resistant inﬂuenza. New
Engl J Med 2009; 360:953–6.
28. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations en-
able the evolution of inﬂuenza oseltamivir resistance. Science 2010;
328:1272–5.
29. Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance
during the 2009 inﬂuenza A H1N1 pandemic: public health,
laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:
240–8.
30. Hurt AC, Deng YM, Ernest J, et al. Oseltamivir-resistant inﬂuenza vi-
ruses circulating during the ﬁrst year of the inﬂuenza A(H1N1) 2009
pandemic in the Asia-Paciﬁc region, March 2009 to March 2010.
Euro Surveill 2011; 16:pii:19770.
31. Leang SK, Deng YM, Shaw R, et al. Inﬂuenza antiviral resistance
in the Asia-Paciﬁc region during 2011. Antiviral Res 2013; 97:
206–10.
32. Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM,
Gubareva LV. Drug susceptibility surveillance of inﬂuenza viruses circu-
lating in the United States in 2011–2012: application of the WHO an-
tiviral working group criteria. Inﬂuenza Other Respir Viruses 2014;
8:258–65.
33. Butler J, Hooper KA, Petrie S, et al. Estimating the ﬁtness advantage
conferred by permissive neuraminidase mutations in recent oseltami-
vir-resistant A(H1N1)pdm09 inﬂuenza viruses. PLoS Pathog 2014;
10:e1004065.
34. Abed Y, Pizzorno A, Bouhy X, Rheaume C, Boivin G. Impact of poten-
tial permissive neuraminidase mutations on viral ﬁtness of the H275Y
oseltamivir-resistant inﬂuenza A(H1N1)pdm09 virus in vitro, in mice
and in ferrets. J Virol 2014; 88:1652–8.
NAI Pan-Resistance in an A(H1N1) Isolate • JID 2015:212 (1 December) • 1733
35. Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread
community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 in-
ﬂuenza in Australia. J Infect Dis 2012; 206:148–57.
36. Takashita E, Ejima M, Itoh R, et al. A community cluster of inﬂuenza
A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and
peramivir in Japan, November to December 2013. Euro Surveill 2014;
19:pii:20666.
37. Yang Z, Yang G, Zhou L. Mutation effects of neuraminidases and their
docking with ligands: a molecular dynamics and free energy calculation
study. J Comput Aided Mol Des 2013; 27:935–50.
38. Abed Y, Boivin G. Treatment of respiratory virus infections. Antiviral
Res 2006; 70:1–16.
39. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-re-
sistant pandemic inﬂuenza A (H1N1) virus. New Engl J Med 2010; 363:
1381–2.
40. Baek YH, Song MS, Lee EY, et al. Proﬁling and characterization of po-
tentially multidrug-resistant inﬂuenza neuraminidase 1 (N1) strains
against neuraminidase inhibitors. J Virol 2015; 89:287–99.
41. Kaiser L. Inﬂuenza will not miss opportunities. Clin Infect Dis 2006;
43:1562–4.
1734 • JID 2015:212 (1 December) • L’Huillier et al
